Special Authorization

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Special Authorization"

Transcription

1 Special Authorization Certain medications in the Reformulary require Special Authorization from your insurance company before your prescription is eligible for coverage. What is Special Authorization? Your drug plan provides you with immediate access to about 10,000 prescription drugs. Certain other medications require Special Authorization before your prescription is eligible for coverage. Will I need to pay for my prescription myself? If the Special Authorization is approved, you will pay the lowest amount (copay) available in your plan for your prescription. If the Special Authorization is not approved, you may need to pay the full price of the prescription yourself. How do I apply for Special Authorization? Your doctor needs to provide a well-documented medical reason why you need to take the Special Authorization drug. Here s how you apply: 1. Complete the Special Authorization (SA) form; you can download the Special Authorization form from your plan administrator s website. Both you and your doctor will need to complete the form. Have your doctor or pharmacist call or fax the Special Authorization (SA) form to your plan administrator. 2. Once your request has been processed, you will be notified and you will also receive a letter in the mail. You will need to have the Special Authorization request approved to pay the lowest amount (co-pay) in your plan. 3. If your plan administrator needs more information, they may contact your doctor directly. 4. If the request is approved, have your prescription filled. If the special authorization request is denied, you and your doctor will be notified. Clinical Conditions in the Reformulary Special Authorization Drugs December

2 What happens to my Special Authorization request once it is sent to my plan administrator? Your request will be confidentially reviewed by a qualified medical reviewer, according to specific criteria. You will receive written notification of the decision, typically within seven to fourteen working days. In cases where a doctor requires an urgent response due to the medical condition, every effort will be made to respond promptly. If your request is approved, the approval will indicate the specified period of time. You will likely need to re-apply for Special Authorization after that specified time period. What if I am already taking a Special Authorization drug? If you are already taking a Special Authorization drug when your new drug plan launches, your drug will be grandfathered. This means that you may continue taking this drug at the lowest amount (co-pay). Please refer to Clinical Conditions in the Reformulary Grandfathered Drugs for more information. Any statement suggesting that you consider a particular drug, indicating that any drug is a preferred drug, or describing the effectiveness of a drug is not intended to be a substitute for your physician's advice, diagnosis or treatment, and should not be used to replace a health care professional, for diagnosis or for treatment. You should not act or rely on any Information provided in this document or in DrugFinder at without seeking the advice of a physician or health care professional. Clinical Conditions in the Reformulary Special Authorization Drugs December

3 ACTEMRA (tocilizumab) ADCIRCA (tadalafil) adefovir ADEMPAS (riociguat) AFINITOR, AFINITOR DISPERZ (everolimus) Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Hepatitis B ALDURAZYME (laronidase) Mucopolysaccharidosis I (MPS I) ALECENSARO (alectinib hydrochloride) APTIOM (eslicarbazepine) APTIVUS (tipranavir) ARANESP (darbepoetin alfa) AUBAGIO (teriflunomide) AVANDIA (rosiglitazone), AVANDAMET (rosiglitazone/metformin) AVONEX (interferon beta-1a) BANZEL (rufinamide) BENLYSTA (belimumab) BETASERON (interferon beta-1b) bosentan BOSULIF (bosutinib) BOTOX (onabotulinumtoxin A) Brenzys (etanercept) BRIVLERA (brivaracetam) butorphanol nasal spray Epilepsy HIV/AIDS Anemia Diabetes ++ Epilepsy Lupus Miscellaneous Conditions Ankylosing Spondylitis; Rheumatoid Arthritis Epilepsy Migraines CALCIJEX (calcitriol) Kidney Disease ++ Clinical Conditions in the Reformulary Special Authorization Drugs December

4 calcitriol (injectable) Kidney Disease ++ CAPRELSA (vandetanib) CARBAGLU (carglumic acid) CARIPUL (epoprostenol) CAYSTON (aztreonam) CELSENTRI (maraviroc) CEREZYME (imiglucerase) Chlorax (clidinium bromide + chlordiazepoxide hydrochloride) CIMZIA (certolizumab) cinacalcet CINQAIR (reslizumab) COPAXONE (glatiramer) COSENTYX (secukinumab) COTELLIC (cobimetinib) CYSTADANE (betaine) DAKLINZA (daclatasvir) DAXAS (roflumilast) deferasirox DIACOMIT (stiripentol) DIFICID (fidaxomicin) DUODOPA (carbidopa + levodopa) EGRIFTA (tesamorelin) ELAPRASE (idursulfase) Hyperammonaemia HIV/AIDS Gaucher Disease Gastrointestinal (GI) Disorders ++ Rheumatoid Arthritis (RA); Psoriatic Arthritis; Ankylosing Spondylitis Hyperparathyroidism; Hypercalcemia Asthma, COPD Ankylosing Spondylitis; Psoriasis; Psoriatic Arthritis Homocystinuria Asthma, COPD Chronic Iron Overload Epilepsy Antibiotics, Antifungals, Antivirals Parkinson s Disease HIV/AIDS Mucopolysaccharidosis II (MPS II) Clinical Conditions in the Reformulary Special Authorization Drugs December

5 ELELYSO (taliglucerase alfa) ENBREL (etanercept) ENTOCORT (budesonide) ENTRESTO (valsartan + sacubitril) ENTYVIO (vedolizumab) EPCLUSA (sofosbuvir + velpatasvir) EPREX (epoetin alfa) ERIVEDGE (vismodegib) erlotinib ESBRIET (pirfenidone) EXJADE (deferasirox) EXTAVIA (interferon beta-1b) EYLEA (aflibercept) FABRAZYME (agalsidase beta) FAMPYRA (fampridine) FERRIPROX (deferiprone) FIRAZYR (icatibant) FLOLAN (epoprostenol) FLUDARA (fludarabine) FORTEO (teriparatide) FOSRENOL (lanthanum carbonate hydrate) FUZEON (enfuvirtide) FYCOMPA (perampanel) GALEXOS (simeprevir) Gaucher Disease Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Juvenile Idiopathic Arthritis (JIA); Ankylosing Spondylitis Inflammatory Bowel Disease (IBD) Heart and Blood Pressure Conditions Inflammatory Bowel Disease (IBD) Anemia Idiopathic Pulmonary Fibrosis Chronic Iron Overload Other Eye Conditions Fabry Disease Iron Overload Hereditary Antioedema (HAE) Osteoporosis Hyperkalemia; Hyperphosphatemia HIV/AIDS Epilepsy Clinical Conditions in the Reformulary Special Authorization Drugs December

6 gefinitib GENOTROPIN (somatropin) GILENYA (fingolimod) GIOTRIF (afatinib) GLEEVEC (imatinib) Grastofil (filgrastim) HARVONI (ledipasvir + sofosbuvir) HEMANGIOL (propranolol hydrochloride) HEPSERA (adefovir) HOLKIRA PAK (ritonavir + paritaprevir + ombitasvir + dasabuvir) HUMATROPE (somatropin) HUMIRA (adalimumab) IBRANCE (palbociclib) ICLUSIG (ponatinib) ILARIS (canakinumab) imatinib IMBRUVICA (ibrutinib) Growth Hormone Deficiency -related Conditions Miscellaneous Conditions Hepatitis B Growth Hormone Deficiency Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Inflammatory Bowel Disease (IBD); Juvenile Idiopathic Arthritis (JIA); Ankylosing Spondylitis; Hidradenitis Suppurativa; Uveitis Juvenile Idiopathic Arthritis (JIA); Cryopyrin- Associated Periodic Syndrome (CAPS); Familial Mediterranean Fever (FMF); Hyperimmunoglobulin D syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD); Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) IMUNOVIR (inosine) Antibiotics, Antifungals, Antivirals ++ INCIVEK (telaprevir) Clinical Conditions in the Reformulary Special Authorization Drugs December

7 Inflectra (infliximab) INLYTA (axitinib) INVEGA TRINZA (paliperidone palmitate) IRESSA (gefitinib) JADENU (deferasirox) JAKAVI (ruxolitinib) JETREA (ocriplasmin) JINARC (tolvaptan) JUXTAPID (lomitapide) KALYDECO (ivacaftor) KEVZARA (sarilumab) KINERET (anakinra) KUVAN (sapropterin) LANCORA (ivabradine) LEMTRADA (alemtuzumab) LENVIMA (lenvatinib mesylate) LIBRAX (clidinium bromide + chlordiazepoxide hydrochloride) linezolid LUCENTIS (ranibizumab) MACUGEN (pegaptanib) MEKINIST (trametinib) METOJECT, METOJECT SUBCUTANEOUS (methotrexate) MODERIBA (ribavirin) Rheumatoid Arthritis; Psoriasis ; Psoriatic Arthritis; Ankylosing Spondylitis; Inflammatory Bowel Disease (IBD) Schizophrenia Chronic Iron Overload Other Eye Conditions Autosomal Dominant Polycystic Kidney Disease (ADPKD) Homozygous familial hypercholesterolemia (HoFH) Rheumatoid Arthritis Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Phenylketonuria Heart and Blood Pressure Disorders Gastrointestinal (GI) Disorders ++ Antibiotics, Antifungals, Antivirals Other Eye Conditions Other Eye Conditions Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Clinical Conditions in the Reformulary Special Authorization Drugs December

8 MULTAQ (dronedarone) Heart and Blood Pressure Conditions ++ MYOZYME (alglucosidase) NAGLAZYME (galsulfase) NEULASTA (pegfilgrastim) NEUPOGEN (filgrastim) NEUPRO (rotigotine) NEXAVAR (sorafenib) nitisinone NORDITROPIN NORDIFLEX (somatropin) NPLATE (romiplostim) NUCALA (mepolizumab) NUTROPIN AQ (somatropin) OFEV (nintedanib esilate) Omnitrope (somatropin) OPSUMIT (macitentan) ORENCIA (abatacept) ORFADIN (nitisinone) ORKAMBI (ivacaftor + lumacaftor) OTEZLA (apremilast) OZURDEX (dexamethasone) PHEBURANE (sodium phenylbutyrate) PLEGRIDY (peginterferon beta-1a) POMALYST (pomalidomide) POSANOL (posaconazole) Pompe's Disease Mucopolysaccharidosis VI (MPS VI, Maroteaux- Lamy syndrome) -related Conditions -related Conditions Parkinson s Disease Hereditary Tyrosinemia type 1 (HT-1) Growth Hormone Deficiency Refractory chronic immune thrombocytopenia purpura (ITP) Asthma, COPD Growth Hormone Deficiency Idiopathic Pulmonary Fibrosis (IPF) Growth Hormone Deficiency Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Hereditary Tyrosinemia type 1 (HT-1) Psoriasis; Psoriatic Arthritis Eye/Ear Inflammation Urea Cycle Disorders Antibiotics, Antifungals, Antivirals Clinical Conditions in the Reformulary Special Authorization Drugs December

9 PRALUENT (alirocumab) PROLASTIN-C (alpha 1-proteinase inhibitor) PULMOZYME (dornase alfa) QUINSAIR (levofloxacin) RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide) RAVICTI (sodium phenylbutyrate) REBIF (interferon beta-1a) REMICADE (infliximab) REMODULIN (treprostinil) RENAGEL (sevelamer hydrochloride) RENVELA (sevelamer carbonate) REPATHA (evolocumab) RESTASIS (ciclosporin) RETISERT (fluocinolone) REVATIO (sildenafil) REVESTIVE (teduglutide) REVLIMID (lenalidomide) REVOLADE (eltrombopag) RILUTEK (riluzole) riluzole RITUXAN (rituximab) SAIZEN (somatropin) High Cholesterol Congenital Alpha 1-Antitrypsin Deficiency Heart and Blood Pressure Conditions ++ Urea Cycle Disorders Rheumatoid Arthritis; Psoriatic Arthritis; Psoriasis; Inflammatory Bowel Disease (IBD); Juvenile Idiopathic Arthritis (JIA); Ankylosing Spondylitis Hyperkalemia; Hyperphosphatemia Hyperkalemia; Hyperphosphatemia High Cholesterol Dry Eye Other Eye Conditions Functional Bowel Disorders ; Refractory chronic immune thrombocytopenia purpura (ITP) Amyotropic Lateral Sclerosis (ALS) Amyotropic Lateral Sclerosis (ALS) Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA) Growth Hormone Deficiency Clinical Conditions in the Reformulary Special Authorization Drugs December

10 SAMSCA (tolvaptan) SAPHRIS (asenapine) SATIVEX (cannabidiol + delta-9- tetrahydrocannabinol) SEBIVO (telbivudine) SENSIPAR (cinacalcet) SIGNIFOR (pasireotide) SIGNIFOR LAR (pasireotide) sildenafil (20 mg) SIMPONI (golimumab) SIMPONI I.V. (golimumab) SOLIRIS (eculizumab) SOMAVERT (pegvisomant) SOVALDI (sofosbuvir) SPRYCEL (dasatinib) STELARA (ustekinumab) STIVARGA (regorafenib) STRENSIQ (asfotase alfa) SUNVEPRA (asunaprevir) SUTENT (sunitinib) tadalafil TAFINLAR (dabrafenib) TAGRISSO (osimertinib) TALTZ (ixekizumab) Hyponatremia Bipolar Disorder Pain Hepatitis B Hyperparathyroidism; Hypercalcemia Cushing's Disease Acromegaly Rheumatoid Arthritis; Psoriatic Arthritis; Inflammatory Bowel Disease (IBD); Ankylosing Spondylitis; Non-Radiographic Axial Spondyloarthritis Rheumatoid Arthritis Hemolytic uremic syndrome (HUS); Paroxysmal nocturnal hemoglobinuria (PNH) Acromegaly Psoriasis; Psoriatic Arthritis; Inflammatory Bowel Disease (IBD) Enzyme Replacement Therapy Psoriasis Clinical Conditions in the Reformulary Special Authorization Drugs December

11 TARCEVA (erlotinib) TASIGNA (nilotinib) TECFIDERA (dimethyl) TECHNIVIE (ritonavir + paritaprevir + ombitasvir) TEMODAL (temozolomide) temozolomide THALOMID (thalidomide) TOBI, TOBI PODHALER (tobramycin) tobramycin (Inhalation Solution) TRACLEER (bosentan) TYKERB (lapatinib) TYSABRI (natalizumab) ULORIC (febuxostat) UPTRAVI (selexipag) VFEND (voriconazole) VICTRELIS (boceprevir) VICTRELIS TRIPLE (boceprevir + peginterferon Alfa- 2B + ribavirin) VIMIZIM (elosulfase alfa) VISUDYNE (verteporfin) VOLIBRIS (ambrisentan) voriconazole (injectable) VOTRIENT (pazopanib) VPRIV (velaglucerase alfa) XALKORI (crizotinib) XELJANZ (tofacitinib) Gout Antibiotics, Antifungals, Antivirals Mucopolysaccharidosis IVA (MPS IVA) Other Eye Conditions Antibiotics, Antifungals, Antivirals Gaucher Disease Rheumatoid Arthritis Clinical Conditions in the Reformulary Special Authorization Drugs December

12 XEOMIN (incobotulinumtoxin A) XIAFLEX (collagenase clostridium histolyticum) XOLAIR (omalizumab) XTANDI (enzalutamide) ZAVESCA (miglustat) ZAXINE (rifaximin) ZELBORAF (vemurafenib) ZEPATIER (elbasvir + grazoprevir) ZINBRYTA (daclizumab beta) ZOLINZA (vorinostat) ZYDELIG (idelalisib) ZYKADIA (ceritinib) ZYTIGA (abiraterone acetate) ZYVOXAM (linezolid) Miscellaneous Conditions Dupuytren's contracture Asthma, COPD; Chronic Idiopathic Urticaria (CIU) Gaucher Disease; Niemann-Pick Disease Type C Hepatic Encephalopathy Antibiotics, Antifungals, Antivirals BRAND drugs are capitalized. Generic drugs are in italics. Symbol denotes grandfathered drugs. Please refer to Clinical Conditions in the Reformulary Grandfathered Drugs for more information ++ Only plan members already taking these drugs may continue to receive coverage for these drugs. Special Authorization will not be given to plan members with a new prescription due to clinical concerns. Clinical Conditions in the Reformulary Special Authorization Drugs December

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

Prior Authorization Approval Guidelines. May, 2017

Prior Authorization Approval Guidelines. May, 2017 Prior Authorization Approval Guidelines May, 2017 Prior Authorization Approval Guidelines Please be advised that in order to be considered for approval, all applicable prior therapies must be listed on

More information

Aetna Better Health. Specialty Drug Program

Aetna Better Health. Specialty Drug Program Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid

More information

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs

Specialty Drugs. The following is a list of medications that are considered to be specialty drugs. Specialty drugs Specialty Drugs The following is a list of medications that are considered to be specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications

More information

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC) INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193

More information

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time.

Specialty Drugs. The specialty drug list below is effective June 5, 2018 and is subject to change at any time. Specialty Drugs The following is a list of medications that are considered specialty drugs. Specialty drugs include self-administered injectables, medications that are high cost, and/or medications that

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of March 31, 2018 207 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of December 31, 2017 196 joint negotiations have been completed** for the following drugs and indications: Drug Product Abilify Maintena

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of May 31, 2018 Pan-Canadian Pharmaceutical Alliance: Completed Negotiations 215 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic Name)

More information

Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016

Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016 Funding Position of CCG Commissioned High Cost Drugs within Lancashire Health Economy Updated February 2016 Drugs can only be recharged to CCGs if used in line with local or national policies as outlined

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of December 31, 2018 262 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017

2018 BCN Advantage Prior Authorization Criteria Last updated: November, 2017 Abstral Actemra Adcirca Adempas Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio Beleodaq

More information

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018

2018 BCN Advantage Prior Authorization Criteria Last updated: April, 2018 Abstral Actemra Adcirca Adempas Aliqopa Afinitor Afinitor- Disperz Alecensa Alunbrig Amitiza Amitriptyline Ampyra Anadrol-50 Androgel Androderm Aralast NP Aranesp Arcalyst Armodafinil Aubagio Avonex Bavencio

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of November 30, 2017 188 joint negotiations have been completed** for the following drugs and indications: Drug Product Abilify Maintena

More information

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015 Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of August 31, 2018 235 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

Biologics for Autoimmune Diseases

Biologics for Autoimmune Diseases Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines

More information

Canada s Rare Disease Strategy: Pathway to Timely Sustainable Access. CADTH Conference

Canada s Rare Disease Strategy: Pathway to Timely Sustainable Access. CADTH Conference Canada s Rare Disease Strategy: Pathway to Timely Sustainable Access CADTH Conference Durhane Wong-Rieger, PhD Canadian Organization for Rare Disorders President & CEO Getting to Sustainable Access What

More information

acromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration

acromegaly Drugs Covered Uses Exclusion Criteria Required Medical Information Age Restriction Prescriber Restriction Coverage Duration acromegaly SIGNIFOR, SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML, 60 MG/0.2 ML, 90 MG/0.3 ML, SOMAVERT SUBCUTANEOUS RECON SOLN 15 MG, 20 MG, 25 MG, 30 MG All medically accepted indications not

More information

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)

More information

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations

Pan-Canadian Pharmaceutical Alliance: Completed Negotiations Pan-Canadian Pharmaceutical Alliance: Completed Negotiations As of September 30, 2018 241 joint negotiations have been completed** for the following drugs and indications: Drug Product Brand Name (Generic

More information

MedStar Medicare Choice Pharmacy Services

MedStar Medicare Choice Pharmacy Services Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page

More information

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or

Exclusion Reasons Presumption of Long- Term Non-Acute Administration C9399 Unclassified Drugs or Noridian Healthcare Solutions, LLC Jurisdiction F Part B Self-Administered Drug (SAD) Exclusion List (A53033); Effective 8/7/2017 The following medications are considered self-administered and are not

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for

More information

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST

METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS

More information

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust

NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust NICE-approved drugs for specialities which fall outside of the services currently provided by the Trust Drug NICE-approved use NICE TA link Abiraterone Abiraterone Adalimumab Adalimumab Adalimumab Adefovir

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)

More information

SELF-ADMINISTERED MEDICATIONS LIST

SELF-ADMINISTERED MEDICATIONS LIST SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607) Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

Pharmacy Services Request Types

Pharmacy Services Request Types FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare

More information

2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA 2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) These drugs require authorization before dispensing

More information

March 2017 Pharmacy & Therapeutics Committee Decisions

March 2017 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary April 1, 2018 Bulletin #169 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: benztropine mesylate, tablet,

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description

CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY. Revision Summary or Description CENTENE PHARMACY & THERAPEUTICS COMMITTEE SECOND QUARTER 2017 AMBETTER GUIDELINE SUMMARY Coverage Guideline Policy & Procedure HIM.PA.32 Long acting stimulants (Adderall XR, Dexedrine, Metadate CD, Ritalin

More information

Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000

Drug Name Generic Name J-Code Unclassified Drugs in excess of $10,000 Unclassified Drugs in excess of $10,000 J3490 Unclassified Biologics in excess of $10,000 J3590 Revenue Codes in excess of $10,000 R250 - R259 ABRAXANE paclitaxel protein-bound J9264 & J9267 ACTEMRA tocilizumab

More information

ACAMPROSATE (CAMPRAL)

ACAMPROSATE (CAMPRAL) ACAMPROSATE (CAMPRAL) ACAMPROSATE CALCIUM Creatinine clearance less than 30 PAGE 1 LAST UPDATED 06/2016 ADALIMUMAB (HUMIRA) HUMIRA, HUMIRA PEDIATRIC CROHN'S, HUMIRA PEN, HUMIRA PEN CROHN'S-UC-HS, HUMIRA

More information

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date

NICE TA Adherence Check list April Drug Indication NICE Approval Release Date NICE TA Adherence Check list April 2014 Drug Indication NICE Approval Release Date Bortezomib Multiple myeloma (induction therapy) Afatinib Rituximab Pixantrone Aflibercept Teriflunomide Fluocinolone acetonide

More information

NICE TA Adherence Check List

NICE TA Adherence Check List NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs

More information

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

ACTEMRA (tocilizumab)

ACTEMRA (tocilizumab) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced

More information

Specialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016

Specialty Overview by Prior Authorization Approval or Denial 2nd Quarter 2016 Specialty Overview by Prior Authorization Approval or 2nd Quarter 2016 3961 DERMATOLOGY Humira RHEUMATOID ARTHRITIS Approval Approved from 04/13/2016 thru 04/13/2018 3961 DERMATOLOGY Stelara PSORIASIS

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 8, 2013 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has

More information

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting

UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting UPMC for You Pharmacy and Therapeutics Committee Meeting April 7, 2014 meeting 1. Call to order: The meeting was called to order at 7:05 a.m. 2. Review of the minutes: The minutes of the January meeting

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

Report generated from MPH Formulary provided by FormularyComplete ( Accessed Formulary Status. TA Number.

Report generated from MPH Formulary provided by FormularyComplete (  Accessed Formulary Status. TA Number. Report generated from MPH provided by Complete (www.pharmpress.com). Accessed 18 01 2016 Title Status Section TA Number TA Link Colecalciferol No UK PL 9.6 Vitamins->9.6.4 Vitamin D->COLECALCIFEROL Colecalciferol

More information

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin #980 August 23, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective August 23, 2018. Included in this bulletin: Regular Benefit Additions Special

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

Specialty Pipeline Update

Specialty Pipeline Update CLINICAL SOLUTIONS Drug Insights > September 2015 Specialty Pipeline Update New Drug Information Xuriden (uridine triacetate): The Food and Drug Administration (FDA) approved Wellstat Therapeutics oral

More information

Otezla. Otezla (apremilast) Description

Otezla. Otezla (apremilast) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background

More information

2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA

2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA 2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) These drugs require authorization before dispensing

More information

ANTI-PARIKSON'S AGENT- DUOPA

ANTI-PARIKSON'S AGENT- DUOPA ANTI-PARIKSON'S AGENT- DUOPA DUOPA Patient has a diagnosis of Parkinson's disease. Patient is levodopa-responsive.patient experiences disabling Off periods for a minimum of 3 hours/day. Disabling Off"

More information

Lista de medicamentos especializados

Lista de medicamentos especializados Lista de medicamentos especializados Vigencia: 1o. de enero de 2016 A continuación se listan, en orden alfabético, los medicamentos de especialidad recetados más frecuentemente. Los medicamentos de especialidad

More information

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation

Date of Guidance Title of Guidance Summary of Recommendations Ratified at Croydon Time to Publication Number Prescribing Committee Implementation NICE Technology Appraisals - Time to Implementation Report - 3 rd August 2015 Produced by Tracy Steadman, Croydon Public Health Intelligence Team, Croydon Council Date of Guidance Title of Guidance Summary

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 04/09/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: 09/05/18 ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 04/09/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: 09/05/18 ARCHIVE DATE: ILARIS (canakinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

DRUGS REQUIRING PRIOR AUTHORIZATION

DRUGS REQUIRING PRIOR AUTHORIZATION DRUGS REQUIRING PRIOR AUTHORIZATION Medication Abstral Actemra Acthar Gel Actiq* Adcirca Adderall Adderall XR Addyi Adempas Adipex* Adzenys XR-ODT Afinitor Afinitor Alecensa Alecensa Ampyra Androderm AndroGel

More information

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude

More information

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz

More information

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD

Prior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):

More information

SPECIALTY PHARMACY Master Clinical Drug List

SPECIALTY PHARMACY Master Clinical Drug List Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None

More information

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio

More information

Specialty Pharmacy Pipeline

Specialty Pharmacy Pipeline Specialty Pharmacy Pipeline Drugs to Watch Anticipated Launches Q1 Q2 2017 Atopic Dermatitis Dupixent (dupilumab) Subcutaneous injection Regeneron Pharmaceuticals/Sanofi moderate-to-severe atopic dermatitis

More information

Center for Evidence-based Policy

Center for Evidence-based Policy P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N

More information

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea

More information

BCN Advantage SM requirements for drugs covered under the medical benefit

BCN Advantage SM requirements for drugs covered under the medical benefit J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central

More information

LIMITED DISTRIBUTION MEDICATIONS

LIMITED DISTRIBUTION MEDICATIONS ACTEMRA IV (USSC can dispense 162 mg PFS) ACTHAR HP ACTIMMUNE ADAGEN ADCETRIS CVS Specialty 1-800-237-2767 1-800-237-2767 ADEMPAS ADVATE ALDURAZYME ALECENSA ALIQOPA ALUNBRIG AMPYRA APOKYN ARALAST NP ARCALYST

More information

Injectable Drugs Requiring Pre-Service Approval

Injectable Drugs Requiring Pre-Service Approval Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier National Quality Strategy Domain:

More information

Specialty Overview by Prior Authorization Approval or Denial 4th Quarter 2016

Specialty Overview by Prior Authorization Approval or Denial 4th Quarter 2016 Specialty Overview by Prior Authorization Approval or 4th Quarter 2016 Carrier Physician Specialty Drug Drug Class Decision Comments Reporting Year Reporting Month 3961 GASTROENTEROLOGY Humira RHEUMATOID

More information

Orphanet Rep rts Series

Orphanet Rep rts Series List of marketing authorised Orphan Drugs in Europe January 2008 Orphan drugs by tradename in alphabetical order Orphan drugs by decreasing of marketing authorisation Orphan drugs in therapeutic areas

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some

More information

Medication Policy Manual. Policy No: dru408. Topic: Site of Care Review Date of Origin: July 10, 2015

Medication Policy Manual. Policy No: dru408. Topic: Site of Care Review Date of Origin: July 10, 2015 Medication Policy Manual Policy No: dru408 Topic: Site of Care Review Date of Origin: July 10, 2015 Committee Approval Date: August 17, 2018 Next Review Date: August 2019 Effective Date: October 1, 2018

More information

Stelara. Stelara (ustekinumab) Description

Stelara. Stelara (ustekinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber

More information

FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)

FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) Brand Generic J Code Covered Uses Required Medical Information and

More information

Drug Formulary Update, October 2016 Commercial and State Programs

Drug Formulary Update, October 2016 Commercial and State Programs Drug Formulary Update, October 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014 Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,

More information